0001193125-25-258790
SEC filingATEC Q3营收$196.5M同比增30%，量驱动增长但诉讼费用激增212%拖累盈利。
| 指标 | 本期 | 去年同期 | 同比 |
|---|---|---|---|
| Revenue | $196,503K | $150,719K | +30% |
| Cost of sales | $59,203K | $47,990K | +23% |
| Gross Profit | $137,300K | $102,729K | +34% |
| Gross Margin | 69.9% | 68.2% | +170 bps |
| Operating Income | $43,270K | $14,287K | +203% |
| Operating Margin | 22.0% | 9.5% | +1250 bps |
| R&D | $18,679K | $20,357K | -8% |
| SG&A | $124,303K | $109,200K | +14% |
| Litigation-related expenses | $6,520K | $2,093K | +212% |
| Total other expense, net | $(12,571)K | $(5,949)K | +111% |
增长桥：Q3营收$196.5M，同比+30%（+$45.8M），九个月$551.2M同比+27%。增长主要由产品销量驱动，源于外科医生用户基数扩大、新产品组合持续扩展及技术采用率提升。公司自2018年转型以来实现约40%的营收复合年增长率。
Margin 归因：Q3 Cost of sales $59.2M同比+23%，增速低于营收的+30%，毛利率由68.2%提升至69.9%（+170 bps），规模效应显现。Operating expenses $153.2M同比+12%，其中SG&A $124.3M同比+14%（与营收增长及分销渠道投入相关），R&D $18.7M同比-8%（主因股权激励费用下降），诉讼费用$6.5M同比+212%。经营利润率由9.5%大幅提升至22.0%（+1250 bps）。
盈利质量：Q3 Total other expense, net为$(12.6)M，同比恶化111%，主因利息净支出$12.9M同比+96%（Braidwell Term Loan增借$50.0M及2030 Notes折摊）。九个月含债务清偿损失$17.6M（2026 Notes赎回）及衍生负债收益$0.6M等一次性项。九个月经营现金流$24.5M转正（去年同期-$55.2M），现金余额$155.7M。
本片MD&A未披露分部级营收或利润数据，故不列分部表。
| 项目 | 2025-09-30 | 2024-12-31 | 变化 |
|---|---|---|---|
| Cash & equivalents | $155,741K | $138,840K | +$16,901K |
| Marketable securities | — | — | — |
| Total Debt | $559,680K | $576,178K | -$16,498K |
| Net Debt | $403,939K | $437,338K | -$33,399K |
| Inventory | $166,890K | $175,264K | -$8,374K |
| RPO / Deferred revenue | $12,150K | $13,598K | -$1,448K |
| Shareholders' Equity | $11,506K | -$14,169K | +$25,675K |